A randomized clinical trial of acellular pertussis vaccines in healthy adults: Dose-response comparisons of 5 vaccines and implications for booster immunization

Journal of Infectious Diseases

Volumn 180, Issue 2, 1999, Pages 397-403

  Keitel, Wendy A ^a   Muenz, Larry R ^b,f   Decker, Michael D ^c   Englund, Janet A ^a,g   Mink, ChrisAnna M ^d,e   Blumberg, Dean A ^e,h   Edwards, Kathryn M ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Tech Resources International Inc   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

^e UCLA MEDICAL CENTER   (United States)

^f Univ of Chicago Hospitals and C ^*  (United States)

^g UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMVAX 1; BIOCINE 3P; CLL 4F; MASS 2; PERTUSSIS VACCINE; PLACEBO; SKB 3P; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BORDETELLA PERTUSSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; ERYTHEMA; FEMALE; HUMAN; IMMUNOGENICITY; INJECTION PAIN; INJECTION SITE; MALE; MULTICENTER STUDY; NORMAL HUMAN; PERTUSSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BORDETELLA PERTUSSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; HUMANS; IMMUNIZATION, SECONDARY; MIDDLE AGED; PERTUSSIS VACCINE; TOXOIDS;

EID: 0033511777     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314869     Document Type: Article

References (33)

1. 1. Mortimer EA. Pertussis and its prevention: a family affair. J Infect Dis 1990;161:473-9.
2. 2. Keitel WA, Edwards KM. Pertussis in adolescents and adults: time to reimmunize? Semin Respir Infect 1995;10:51-7.
3. 3. Deen JL, Mink CM, Cherry JD, et al. Household contact study of B. pertussis infections. Clin Infect Dis 1995;21:1211-9.
4. 4. Mink CM, Cherry JD, Christenson PD, et al. A search for Bordetella pertussis infection in university students. Clin Infect Dis 1992;14:464-71.
5. 5. Wright SW, Edwards KM, Decker MD, Zeldin MH. Pertussis infection in adults with persistent cough. JAMA 1995;273:1044-6.
6. 6. Lambert HJ. Epidemiology of small pertussis outbreak in Kent County. Public Health Rep 1965;80:365-9.
7. 7. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Br Med J (Clin Res Ed) 1988;296:612-4.
8. 8. Ipsen J, Bowen HE. Effects of routine immunization of children with triple vaccine (Diphtheria-Tetanus-Pertussis). Am J Public Health 1955;45: 312-8.
9. 9. Klein DL. Preface-Multicenter acellular pertussis vaccine trial: a National Institutes of Health perspective. Pediatrics 1995;96(Suppl):547-8.
10. 10. Volk VK, Gottshall RY, Anderson HD, Top FH, Bunney WE, Serfling RE. Antibody response to booster dose diphtheria and tetanus toxoids and pertussis vaccine: thirteen years after inoculation of institutionalized subjects. Public Health Reports 1964;79:424-34.
11. 11. Linnemann CC, Ramundo N, Perlstein PH, Minton SD, Englender GS. Use of pertussis vaccine in an epidemic involving hospital staff. Lancet 1975;2: 540-4.
12. 12. Hederstedt B, Granstrom M. Adverse reactions and antibody response to an acellular pertussis toxoid vaccine in adult volunteers. Vaccine 1989;7: 349-50.
13. 13. Granstrom M, Thoren M, Blennow M, Tiru M, Sato Y. Acellular vaccine in adults: adverse reactions and immune responses. Eur J Clin Microbiol 1987;6:18-21.
14. 14. Sekura R, Zhang Y, Roberson R, et al. Clinical, metabolic, and antibody responses of adult volunteers to an investigational vaccine composed of pertussis toxin inactivated by hydrogen peroxide. J Pediatr 1988;113: 806-13.
15. 15. Ruuskanen O, Noel A, Putto-Laurila A, et al. Development of an acellular pertussis vaccine and its administration as a booster in healthy adults. Vaccine 1991;9:117-21.
16. 16. Podda A, Nencioni L, Marsili I, et al. Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa. Vaccine 1991;9:741-5.
17. 17. Englund JA, Glezen WP, Barreto L. Controlled study of a new five-component acellular pertussis vaccine in adults and young children. J Infect Dis 1992;166:1436-41.
18. 18. Edwards KM, Decker MD, Graham BS, Mezzatesta J, Scott J, Hackell J. Adult immunization with acellular pertussis vaccine. JAMA 1993;269: 53-6.
19. 19. Meade BD, Adamadia D, Edwards KM, et.al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics 1995;96(Suppl): 570-6.
20. 20. Decker MD, Edwards KM, Steinhoff MC, et.al. Comparison of a 13 acellular pertussis vaccine: Adverse reactions. Pediatrics 1995;96(Suppl):557-66.
21. 21. Edwards KM, Meade BD, Decker MD, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995; 96(Suppl):548-57.
22. 22. Pichichero ME, Deloria MA, Rennels MB, et al. A safety and immunogenicity comparison of 12 acellular vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15 to 20 month old children. Pediatrics 1997;100(5):772-8.
23. 23. Pappenheimer AM. Diphtheria. In Germanier R, ed. Bacterial Vaccines. Orlando: Academic. 1984:1-36.
24. 24. Burdette WJ, Gehan EA. Planning and analysis of clinical studies. Springfield, IL: Thomas, 1970.
25. 25. Shahin RD, Brennan MJ, Li ZM, Meade BD, Manclark CR. Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis. J Esp Med 1990;171:63-73.
26. 26. Lopez AL, Blumberg DA. An overview of the status of acellular pertussis vaccines in practice. Drugs 1997;54:189-96.
27. 27. Sato Y, Izumiya K, Sato H, Cowell JL, Manclark CR. Role of antibody to leukocytosis-promoting factor hemagglutinin and to filamentous hemagglutinin in immunity to pertussis. Infect Immun 1981;31:1223-31.
28. 28. Granstrom M, Granstrom G. Serological correlates in whooping cough. Vaccine 1993;11:445-8.
29. 29. He Q, Viljanen MK, Olander R-M, Bogaerts H, et al. Antibodies to filamentous hemagglutinin of Bordetella pertussis and protection against whooping cough in schoolchildren. J Infect Dis 1994;170:705-8.
30. 30. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illness. Vaccine 1998;16: 1901-6.
31. 31. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of antipertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998;16:1907-16.
32. 32. Hewlett EL. Pertussis: current concepts of pathogenesis and prevention. Pediatr Infect Dis J 1997;16(Suppl):S78-S84.
33. 33. Mills KHG, Ryan M, Ryan E, Mahon BP. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 1998;66:594-602.